This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Adaptimmune Therapeutics’s 8K filing here.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
See Also
- Five stocks we like better than Adaptimmune Therapeutics
- Most active stocks: Dollar volume vs share volume
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- Stock Market Sectors: What Are They and How Many Are There?
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Retail Stocks Investing, Explained
- Top Nuclear Stocks Thriving on Soaring Energy Demand
